50. Denosumab

  1. Clifford J. Rosen MD
  1. Michael R. McClung

Published Online: 19 JUL 2013

DOI: 10.1002/9781118453926.ch50

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

How to Cite

McClung, M. R. (2013) Denosumab, in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition (ed C. J. Rosen), John Wiley & Sons, Inc., Ames, USA. doi: 10.1002/9781118453926.ch50

Publication History

  1. Published Online: 19 JUL 2013

ISBN Information

Print ISBN: 9781118453889

Online ISBN: 9781118453926

SEARCH

Keywords:

  • bone mineral density (BMD);
  • bone turnover;
  • denosumab;
  • osteoporosis;
  • RANKL

Summary

Denosumab is the first inhibitor of receptor activator of nuclear factor κ-B ligand (RANKL) available for the treatment of osteoporosis and other bone diseases. Inhibition of RANKL can reduce bone resorption in a clinical setting. Denosumab was effective in increasing bone density and decreasing the incidence of vertebral fracture in women of the FREEDOM trial, a fracture end point study, across the spectrum of baseline renal function. Denosumab would likely be effective in treating Paget's disease of bone and in controlling hypercalcemia related to malignancy. In postmenopausal women with osteoporosis, denosumab is at least as effective as other potent antiresorptive agents in reducing the risk of clinically important fractures. Denosumab also prevents bone loss in postmenopausal women without osteoporosis and in patients receiving hormone ablation therapy for nonmetastatic cancer, and it is likely to be effective in treating men with low bone mass.